Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70.

CAS  Article  Google Scholar 

Ching C, Eslick GD, Poulton AS. Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. JAMA Pediatr. 2019;173(7):630–9.

Article  Google Scholar 

Dursteler KM, Berger EM, Strasser J, Caflisch C, Mutschler J, Herdener M, Vogel M. Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Subst Abuse Rehabil. 2015;6:61–74.

Article  Google Scholar 

Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, Reed S, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014;109(9):1489–500.

Article  Google Scholar 

Krinzinger H, Hall CL, Groom MJ, Ansari MT, Banaschewski T, Buitelaar JK, Carucci S, Coghill D, Danckaerts M, Dittmann RW, et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev. 2019;107:945–68.

CAS  Article  Google Scholar 

Shellenberg TP, Stoops WW, Lile JA, Rush CR. An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations. Expert Rev Clin Pharmacol. 2020;13(8):825–33.

CAS  Article  Google Scholar 

Hofmans L, Papadopetraki D, van den Bosch R, Määttä JI, Froböse MI, Zandbelt BB, Westbrook A, Verkes RJ, Cools R. Methylphenidate boosts choices of mental labor over leisure depending on striatal dopamine synthesis capacity. Neuropsychopharmacology. 2020;45(13):2170–9.

CAS  Article  Google Scholar 

Winstock AR, Maier LJ, Zhuparris A, Davies E, Puljevic C, Kuypers KPC, Ferris JA, Barratt MJ. Global Drug Survey (GDS) 2021 Key Findings Report. 2021.

Wang H, Deng J, Zhou X, Lu C, Huang J, Huang G, Gao X, He Y. The nonmedical use of prescription medicines among high school students: A cross-sectional study in Southern China. Drug Alcohol Depend. 2014;141:9–15.

Article  Google Scholar 

Johnston LD, Miech RA, O'malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the Future National Survey Results on Drug use 1975-2021: Overview, Key Findings on Adolescent Drug Use. Institute for Social Research, University of Michigan. 2022:16. Available online at: https://deepblue.lib.umich.edu/bitstream/handle/2027.42/171751/mtf-overview2021.pdf?sequence=1&isAllowed=y. Accessed 20 April 2022.

Gheshlaghi LA, Sharifi H, Darabib M, Chegenia M, Khalili M, Noroozi A, Rajaei L, Ardalan G, Tohidinik HR. Prevalence of amphetamine-type stimulants use in Iran: a systematic review and meta-analysis. J Subst Use 2021;26(6):569–585. https://doi.org/10.1080/14659891.2021.1879289.

Wise RA, Robble MA. Dopamine and Addiction. Annu Rev Psychol. 2020;71:79–106.

Article  Google Scholar 

McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100(9):1320–9.

Article  Google Scholar 

Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809–18.

Article  Google Scholar 

Glasner-Edwards S, Rawson R. Evidence-based practices in addiction treatment: Review and recommendations for public policy. Health Policy. 2010;97(2):93–104.

Article  Google Scholar 

Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict. 2008;17(1):24–7.

Article  Google Scholar 

Zhong J, Tang Y, Li Z, Liu X. Correlation Analyses of the Drug Abuse Motivation of Heroin Addicts and Their Addiction Behavior. Journal of Southwest University(Natural Science Edition). 2008;8:165–8. http://fx.sjtulib.superlib.net/detail_38502727e7500f26af03e8e75eb2e18c46e0093dbefb2a451921b0a3ea255101fc1cf1fbb4666ae6abf68a60df16f3d0b4e422a4f05f8d154e1cce4d19f4863f834be5561a72109dbc6947ea96207004.

Hamilton M. A rating scale for depression[J]. Journal of neurology, neurosurgery, and psychiatry. 1960;23(1):56-62. https://doi.org/10.1136/jnnp.23.1.56.

Wang YY, Jiang NZ, Cheung EF, Sun HW, Chan RC. Role of depression severity and impulsivity in the relationship between hopelessness and suicidal ideation in patients with major depressive disorder. J Affect Disord. 2015;183:83–9.

Article  Google Scholar 

Liu Z, Qiao D, Xu Y, Zhao W, Yang Y, Wen D, Li X, Nie X, Dong Y, Tang S, et al. The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial. J Med Internet Res. 2021;23(5): e26883.

Article  Google Scholar 

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–5.

CAS  Article  Google Scholar 

Khansa W, Haddad C, Hallit R, Akel M, Obeid S, Haddad G, Soufia M, Kheir N, Abi Elias Hallit C, Khoury R, et al. Interaction between anxiety and depression on suicidal ideation, quality of life, and work productivity impairment: Results from a representative sample of the Lebanese population. Perspect Psychiatr Care. 2020;56(2):270–9.

Article  Google Scholar 

Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev. 2010;35(2):157–71.

CAS  Article  Google Scholar 

Acquas E, Di Chiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J Neurochem. 1992;58(5):1620–5.

CAS  Article  Google Scholar 

Jarman SK, Haney AM, Valdez GR. Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol. PLoS ONE. 2018;13(9): e0205016.

Article  Google Scholar 

Ferreira R, Bassi GS, Cabral A, Nobre MJ. Withdrawal from methylphenidate increases neural reactivity of dorsal midbrain. Neurosci Res. 2010;68(4):290–300.

CAS  Article  Google Scholar 

Krakowski A, Ickowicz A. Stimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report. J Can Acad Child Adolesc Psychiatry. 2018;27(2):148–51.

PubMed  PubMed Central  Google Scholar 

Grau-Lopez L, Daigre C, Mercado N, Casas M, Roncero C. Dystonia in Methylphenidate Withdrawal: A Case Report. J Addict Med. 2017;11(2):154–6.

Article  Google Scholar 

Levi MS, Divine B, Hanig JP, Doerge DR, Vanlandingham MM, George NI, Twaddle NC, Bowyer JF. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle. Neurotoxicol Teratol. 2012;34(2):253–62.

CAS  Article  Google Scholar 

Boyette-Davis JA, Rice HR, Shoubaki RI, Gonzalez CMF, Kunkel MN, Lucero DA, Womble PD, Guarraci FA. A recreational dose of methylphenidate, but not methamphetamine, decreases anxiety-like behavior in female rats. Neurosci Lett. 2018;682:21–6.

CAS  Article  Google Scholar 

Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P. From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate. Curr Neuropharmacol. 2016;14(1):17–27.

Article  Google Scholar 

Keane H. Pleasure and discipline in the uses of Ritalin. Int J Drug Policy. 2008;19(5):401–9.

Article  Google Scholar 

Hildt E, Lieb K, Bagusat C, Franke AG. Reflections on Addiction in Students Using Stimulants for Neuroenhancement: A Preliminary Interview Study. Biomed Res Int. 2015;2015: 621075.

Article  Google Scholar 

Ram SS, Hussainy S, Henning M, Jensen M, Russell B. Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug Alcohol Rev. 2016;35(3):345–51.

Article  Google Scholar 

León KS, Martínez DE. To Study, to Party, or Both? Assessing Risk Factors for Non-Prescribed Stimulant Use among Middle and High School Students. J Psychoactive Drugs. 2016;49(1):22–30.

Article  Google Scholar 

Mendelson JE, Maier LJ, Liechti ME, Herzig F, Schaub MP. To Dope or Not to Dope: Neuroenhancement with Prescription Drugs and Drugs of Abuse among Swiss University Students. PLoS ONE. 2013;8(11):e77967.

Article  Google Scholar 

Moszczynska A, Callan SP. Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment. J Pharmacol Exp Ther. 2017;362(3):474–88.

CAS  Article  Google Scholar 

García-Cabrerizo R, García-Fuster MJ. Methamphetamine binge administration dose-dependently enhanced negative affect and voluntary drug consumption in rats following prolonged withdrawal: role of hippocampal FADD. Addict Biol. 2019;24(2):239–50.

Article  Google Scholar 

Fernando WWSA, Wellman RJ, DiFranza JR. The relationship between level of cigarette consumption and latency to the onset of retrospectively reported withdrawal symptoms. Psychopharmacology. 2006;188(3):335–42.

CAS  Article  Google Scholar